INTS
Price:
$0.4603
Market Cap:
$21.70M
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with ...[Read more]
Industry
Biotechnology
IPO Date
2023-06-30
Stock Exchange
NASDAQ
Ticker
INTS
According to Intensity Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 14.75M. This represents a change of -0.96% compared to the average of 14.90M of the last 4 quarters.
The mean historical Enterprise Value of Intensity Therapeutics, Inc. over the last ten years is 64.73M. The current 14.75M Enterprise Value has changed 2.18% with respect to the historical average. Over the past ten years (40 quarters), INTS's Enterprise Value was at its highest in in the December 2023 quarter at 109.09M. The Enterprise Value was at its lowest in in the June 2021 quarter at 0.
Average
64.73M
Median
71.88M
Minimum
22.02M
Maximum
81.25M
Discovering the peaks and valleys of Intensity Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 9.56%
Maximum Annual Enterprise Value = 81.25M
Minimum Annual Increase = -66.35%
Minimum Annual Enterprise Value = 22.02M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 22.02M | -66.35% |
| 2023 | 65.44M | -19.46% |
| 2022 | 81.25M | 7.09% |
| 2021 | 75.88M | 9.56% |
| 2020 | 69.25M | -7.05% |
The current Enterprise Value of Intensity Therapeutics, Inc. (INTS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
56.24M
5-year avg
62.77M
10-year avg
64.73M
Intensity Therapeutics, Inc.’s Enterprise Value is greater than Iterum Therapeutics plc (10.14M), less than Rallybio Corporation (18.77M), greater than iBio, Inc. (-4380600.00), less than Pluri Inc. (46.18M), less than Boundless Bio, Inc. (59.44M), greater than Sonnet BioTherapeutics Holdings, Inc. (8.18M), less than Plus Therapeutics, Inc. (26.35M), less than NextCure, Inc. (33.89M), greater than AN2 Therapeutics, Inc. (10.96M), greater than Q32 Bio Inc. (6.85M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 10.14M | $21.14M | |
| 18.77M | $28.16M | |
| -4380600.00 | $21.16M | |
| 46.18M | $23.49M | |
| 59.44M | $24.62M | |
| 8.18M | $8.43M | |
| 26.35M | $39.62M | |
| 33.89M | $34.11M | |
| 10.96M | $29.18M | |
| 6.85M | $44.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intensity Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Intensity Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Intensity Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Intensity Therapeutics, Inc. (INTS)?
What is the 3-year average Enterprise Value for Intensity Therapeutics, Inc. (INTS)?
What is the 5-year average Enterprise Value for Intensity Therapeutics, Inc. (INTS)?
How does the current Enterprise Value for Intensity Therapeutics, Inc. (INTS) compare to its historical average?